Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Solid is here and intend to stay long and strong. GRPS.
Tomorrow's NSAV shareholder conference call will be at 10:00 AM EST (Friday, July 9, 2021) and feature NSAV Director, Mr. Yuen Wong, who is also the CEO of LABS Group labsgroup.io and Managing Director of major Cryptocurrency Exchange Bitmart bitmart.com https://twitter.com/nsavtech/status/1413209504255299589?s=21
Tomorrow, NSAV will also reveal the launch date for its wholly owned Cryptocurrency Exchange. Thank you.
nsavholdinginc.com https://twitter.com/nsavtech/status/1413210342277238787?s=21
I BELIEVE!!! $$$NSAV$$$
Being a very long RSHN shareholder I'm very impressed with Ahley's leadership and transparency! $$$RSHN$$$
THE GAME BEGUN!!! $$$NSAV$$$
RushNet, Inc Closes the Acquisition of heliosDX which Brings Significant Revenues to the Company
Press Release | 07/08/2021
ALPHARETTA, GA / ACCESSWIRE / July 8, 2021 / RushNet, Inc (OTC PINK:RSHN), ("the Company") is pleased to announce the acquisition of heliosDX was closed and effective July 1, 2021.
heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. This acquisition brings significant value to RushNet, Inc and its shareholders.
heliosDX had annual revenues in 2019 of $2,639,454.58, 2020 of $4,294,435.82, and in 2021 through the 2nd Quarter of $2,827,582.50. heliosDX expects their current trends to hold and should meet their stretch goal of $6,000,000 for 2021. The company is profitable and has seen profits continue to grow right alongside the revenue growth. The company is also under a Binding Letter of Intent to acquire a privately held Laboratory slated to close late 3rd Quarter or early 4th Quarter. This acquisition will immediately bring heliosDX annual revenues to over $16,000,000 with a tremendous upside.
The combined operations vastly increase the heliosDX specimen capacity, sales representatives, and creates room for future growth in their infectious disease business, which is expected to outpace toxicology within 12 months. In a separate transaction, the company is seeking to purchase the building that the private company currently occupies, which includes an empty space attached for future expansion. This first acquisition should yield annual revenues for heliosDX of $25,000,000 after a full 12 months of combined operations. We believe, as we continue to grow organically, along with acquisitions, we can reach and exceed $50,000,000 in annual revenue within two years.
Currently, heliosDX is in Alpharetta, GA which will remain the laboratory headquarters after the acquisition of the private laboratory. The company also just negotiated a new lease in Orange Park, Florida (Oakleaf Area) to open executive offices with an anticipated opening date of August 1, 2021. heliosDX recently announced via their Twitter page (https://twitter.com/dx_helios) they are actively seeking board members and expect to announce members throughout the 3rd Quarter.
heliosDX is launching a National Sales Campaign utilizing Verb's interactive technology and hired a Director of Virtual Sales to run this platform. This platform is anticipated to begin on August 1, 2021. We believe this platform will significantly increase the company's ability to reach new clients at a fraction of the cost across the country. In late June 2021, heliosDX extended an offer to hire a Chief Operations Officer (COO), which has been accepted with a start date of August 2, 2021. Other executive positions are currently being explored and formal job postings will be made available on the company's LinkedIn business page.
RushNet, Inc and heliosDX have significant plans to reduce the current share structure. We are not prepared at this time to disclose the nature of this reduction but can confirm it is not through a Reverse Split (RS).
About HeliosDx:
heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Contact:
Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com
Twitter Handle: @dx_helios
https://www.otcmarkets.com/stock/RSHN/news/RushNet-Inc-Closes-the-Acquisition-of-heliosDX-which-Brings-Significant-Revenues-to-the-Company?id=310736
"Jake from State Farm? What are you wearing Jake?" LOL.
Products needed produce sales and they are needed now. GRPS.
AGREE! GLTA!
NSAV ANNOUNCES LAUNCH OF NFT WITH LABS GROUP, THE WORLD’S FIRST COMMUNITY POWERED AND OWNED NFT RESORT
Press Release | 07/06/2021
Net Savings Link, Inc. (OTC: NSAV), a cryptocurrency, blockchain and digital asset technology company, today announced that it has teamed up with LABS Group https://labsgroup.io/ to launch the worlds first community powered and owned NFT (Non-Fungible Token) resort. The new resort will be fractionalized into 365 RTS (Rewarding Timeshare)-NFTs, exclusively listed on the Refinable Marketplace https://refinable.co/ . The NFTs will be sold via an auction beginning July 15. All opening bids will start at the cost base price. Refinable is the first dedicated NFT marketplace built on Binance Smart Chain (BSC) https://www.binance.org/en/smartChain . The Flagship NFT resort will be located near the historic and world- renowned tourist and cultural destination of Bali, Indonesia.
Todays announcement reflects the explosive growth and expanding applicability of the NFT marketplace sector. According to NonFungible.com, over $2 billion was spent on non-fungible tokens during the first quarter of 2021 an increase of about 2,100% from Q4 2020 and already far surpassing the $250 million NFT market in 2020. The management of NSAV believes that now is the perfect time to enter the NFT market.
NSAV will hold a shareholder conference call later this week to provide more details on the NFT project. The exact date and time of the shareholder conference call will be announced on Wednesday. The Company will also update shareholders on the status of NSAVs Cryptocurrency Exchange, which was officially announced last week.
Mr. Yuen Wong, Director of NSAV and CEO of LABS Group stated, We are thrilled to announce the world's first community powered and owned NFT fractionalized Resort.
The rewards and rights will be allocated to each of the 365 NFTs and collectively they represent the entire interest of the glamping concept resort. Now everyone can participate in direct resort investment and recreation deals. After the conference call, we are certain that all NSAV shareholders will come to realize the ecosystem that we are pioneering and building.
Mr. Wong will be on this weeks NSAV shareholder conference call.
Mr. Wong is also a Managing Partner at Bitmart Cryptocurrency Exchange https://www.bitmart.com . BitMart is a premier global digital asset trading platform with over 2 million users worldwide and ranked among the top crypto exchanges on CoinMarketCap. Bitmarts platform supports over 220 cryptocurrencies and has a 24 hour trading volume of approximately $2 Billion.
About LABS Group
LABS Group is a digital investment platform that provides access to fractionalized property ownership and enables the continuous trading of real estate assets-backed tokenized shares on a regulated security exchange.
LABS Groups platform uses blockchain technology and smart contracts to ensure complete transparency over a borderless ecosystem where property developers and investors can interact seamlessly and with unprecedented efficiency.
Real estate and blockchain professionals have brought together their expertise to devise an ecosystem of services that make property investment more accessible, more secure, and more liquid.
For more information on LABS Group, feel free to follow our socials below:
LinkedIn: https://www.linkedin.com/company/labs-group/
Website: https://labsgroup.io/
Instagram: https://www.instagram.com/labsgroupio/
Telegram: https://t.me/labsgroupio
Twitter: https://twitter.com/labsgroupio
Project Page: https://gravityresortskk.labsgroup.io/
NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the cryptocurrency, blockchain and digital asset industries. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services and information technology.
For further information please contact NSAV at info@nsavholdinginc.com
The NSAV Twitter account can be accessed at https://twitter.com/nsavtech
The NSAV corporate website can be accessed at http://nsavholdinginc.com
https://www.otcmarkets.com/stock/NSAV/news/NSAV-ANNOUNCES-LAUNCH-OF-NFT-WITH-LABS-GROUP-THE-WORLDS-FIRST-COMMUNITY-POWERED-AND-OWNED-NFT-RESORT?id=310255
Halberd Corporation CEO Letter
Press Release | 07/06/2021
https://www.otcmarkets.com/stock/HALB/news/Halberd-Corporation-CEO-Letter?id=310275
RushNet, Inc with heliosDX Announces Roadmap Update, Dividend Enhancements, and Acquisition Update
Press Release | 07/06/2021
ALPHARETTA, GA / ACCESSWIRE / July 6, 2021 / RushNet, Inc. (OTC PINK:RSHN), ("the Company") with target acquisition heliosDX, is pleased to announce an update to the Roadmap, which was included in the June 1, 2021 Press Release. We will also highlight the spinoff dividend enhancement, and acquisition for heliosDX and RushNet, Inc.
Completed:
Filing Disclosures
Filing Financials
Attorney Letter
Mid/2nd Quarter Financial Update (Record Breaking)
Pink Current
Website transition chattahoocheelabs.com to heliosDX.com
Professional Sales and Marketing Video
R/S Officially Canceled
*NEW: Hiring a Director of Virtual Sales - Completed
In Progress and Updates:
Audit Financials - Will Reach Satisfactory Audit
Spinoff RushNet, Inc Subsidiaries - Hold; Pending heliosDX Spinoff
Lab Acquisition(s) and/or LOI Update - Target Close Date Late 3rd Quarter
Complete the Merger/Acquisition (heliosDX by RushNet) - Imminent
Reengage FINRA - Part of Spinoff Process
SEC Reporting - Pending Spinoff
Preparation of Application to SEC & FINRA
Launch National Sales Campaign Utilizing Verb Technologies - August 1, 2021
New Items:
heliosDX Opening Executive Offices in Florida - Pending RushNet Acquisition of Grandeza Healthcare -In ProgressLease Signature
Announcement of Board Members - Coming in 3rd Quarter
Hiring of Executive Team - Ongoing, Will post positions VIA LinkedIn
We previously announced upon the spinoff of heliosDX, the RushNet, Inc shareholders would have access and receive the following:
Receive One Share of heliosDX per 1,000 shares of RushNet owned upon close on the ex-dividend date.
RushNet shareholders would have access to purchase 11 shares of heliosDX per 1,000 shares of Rushnet, Inc at a discount to market upon the close on the ex-dividend date.
Rushnet shareholders as of the close on the ex-dividend date would also receive a dividend in the legacy RushNet, Inc upon spinoff. The dividend is yet to be determined.
Example: If you owned 1,000,000 of RushNet upon close on the ex-dividend date you would receive 1,000 shares of heliosDX. You would also have the exclusive right to purchase 11,000 additional shares of heliosDX at a discount to market. You also receive a dividend in the RushNet legacy to be spun off later.
Since heliosDX burst onto the public scene approximately 90 days ago, we have stressed transparency and shareholder value. These two pillars remain constant today. Previously, we announced the signing of a Binding Letter of Intent with a Privately held Laboratory, which would triple heliosDX annual revenue. In addition, the acquisition also significantly increases the company's bandwidth and sales reach. heliosDX has demonstrated over the last few years the ability to drive test volume and revenue. The company had annual revenues in 2019 of $2.6M, 2020 of $4.29M, and in 2021 trending $6M. We have also seen the profitability of the company follow right along. We believe, as we continue to grow organically, along with acquisitions we can reach $50,000,000 in annual revenue in two years. This first acquisition should yield annual revenues for heliosDX of $25,000,000 after a full 12 months. The exclusive offering to RushNet shareholders is paramount to current and future acquisitions. heliosDX does not need funds for ongoing operations. As mentioned, we are profitable and have been profitable. The proceeds from the exclusive offering are solely for company growth and acquisition(s). This drives company value, and equally important, shareholder value.
Finding a balance with the spinoff dividend to drive shareholder value and allow the company to raise the funds necessary to complete the acquisition(s) is vital. With that in mind, below is the enhanced spinoff dividend and exclusive discount offer to RushNet Inc shareholders.
Receive One Share of heliosDX per 800 shares of RushNet owned upon close on the ex-dividend date.
RushNet shareholders have access to purchase 11 additional shares of heliosDX per 1,000 shares of Rushnet, Inc at a 50% to market upon the close on the ex-dividend date.
For every 10 shares purchased during the offering period at the discount to market of 50% the shareholder receives one additional share of heliosDX
The offering price of heliosDX will be preacquisition
Rushnet shareholders as of the close on the ex-dividend date would also receive a dividend in the legacy RushNet, Inc upon spinoff. This dividend is yet to be determined.
Example: If you owned 1,000,000 of RushNet upon close on the ex-dividend date you would receive 1,250 shares of heliosDX. You would also have the exclusive right to purchase 11,000 additional shares of heliosDX at a 50% discount to market. Now, if you bought 5,000 shares at the discount during the offering period you would receive an additional 1 share for every 10 shares purchased or in this case 500 shares.
Should heliosDX not raise a minimum of $8,000,000 in funding for acquisitions and future growth, we would then seek a more traditional offering to raise the funds necessary to accomplish the company's initiatives. Also note, the ex-dividend date will be set once the audits are finalized and the application is submitted to the appropriate channels. In an effort to stay timely, the documents are being prepared so that a an immediate submission can occur upon completion of the audits.
RushNet, Inc will also acquire Grandeza Healthcare in the near term which is the sister company of heliosDX. Grandeza will achieve over $1,500,000 in annual revenue and be profitable in year one of operations. Grandeza is a billing and coding company in the healthcare sector and believes it can achieve over $3,000,000 in annual revenue in 2022. We believe Grandeza is the perfect addition to RushNet post spinoff of heliosDX. It is a fast-growing company, which can bring long-term value to RushNet, Inc in addition to the heliosDX dividend and offering value.
About HeliosDx:
heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Contact:
Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com
Twitter Handle: @dx_helios
View source version on accesswire.com:
https://www.accesswire.com/654340/RushNet-Inc-with-heliosDX-Announces-Roadmap-Update-Dividend-Enhancements-and-Acquisition-Update
GREAT NEWS! $$$NSAV$$$
Going higher from here tomorrow. $$$NSAV$$$
Just bought more $$$NSAV$$$.
You have to be able behind small fragments to see the overall picture. There is no turning back. $$$NSAV$$$.
Thank you Bonous. $$$NSAV$$$
CORRECTION: RushNet Inc. with Acquisition Target heliosDX Release Preliminary 2nd Quarter Results
This press release is updated with the correct date in the dateline.
ALPHARETTA, GA / ACCESSWIRE / June 30, 2021 /RushNet, Inc (OTC PINK:RSHN) ("RushNet") with Acquisition target heliosDX is excited to release preliminary Quarter 2 results for 2021. In the 2nd Quarter of 2021, heliosDX continued to show strength Quarter over Quarter (QOQ) with outstanding results. The first Quarter of 2021 was a record-breaking quarter for the company. We set company benchmarks for revenue, gross profit, individual monthly revenue, and specimens processed for the quarter. The first quarter of 2021 was truly an amazing quarter for heliosDX, especially coming off the record setting year in 2020. We did however see our net profit take a dive in the first quarter of 2021 due to the added spend of expanding our instrument capacity and testing capabilities. That coupled with the added expenses of beginning the process of going public weighed heavily. heliosDX was fortunate to be able to absorb all these costs by taking a temporary hit to the bottom line. We did not need additional funding or toxic debt to accomplish these feats.
Now, let us dive into the 2nd Quarter of 2021:
Quarter 2 saw Record Revenue at an estimated $1.56M verses a stretch target of $1.4M. This is an increase QOQ of approximately $300,000 or 23.91%
We outperformed our stretch target by 11.43%
We will post Gross Profit for the second Quarter at an estimated $1.256M verses Gross Profit in Quarter 1 of $1.001M. This is an increase QOQ of approximately $255,000 or 25.47%.
We will also post an estimated profit in Quarter 2 of $226,789 verses Quarter 1 profit of $40,737. This is an estimated increase QOQ of $186,052 or 456.72%
We also processed a record number of specimens in Quarter 2 at an estimated 6,842 verses Quarter 1 at 6,488. This is an increase of 354 specimens or 5.46%.
The company also set a new benchmark in May 2021 of approximately $530,000 in Monthly Revenue. This did not last long, in June 2021 heliosDX will post an estimated $570,000 in monthly revenue.
The company's previous monthly specimen benchmark was approximately 2,500, which was also topped in June 2021 at an estimated 2,800 specimens processed.
These results are coming off a paramount year in 2020 when the company realized an increase in revenue from 2019 by $1.655M. The 2nd Quarter results are a clear indication heliosDX is executing in all phases of their business. heliosDX believes there is still a lot of room for growth in all phases, while continuing to increase the company margins and furthering our organic growth. We are starting to see our profits rise as the spending continues to decrease from our instrument and testing enhancements. However, Quarter 3 will see additional spending as the company prepares to take the next step to become a fully reporting publicly traded entity. In addition, the company will have additional spend towards the acquisition announced previously. This acquisition will triple the company's revenue and drastically increase specimen capacity and market reach.
RushNet, Inc combined with heliosDX is also expected to close on their transaction by July 12, 2021, to officially bring heliosDX into RushNet, Inc.
About HeliosDx:
heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Contact:
Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com
Twitter Handle: @dx_helios
https://finance.yahoo.com/news/correction-rushnet-inc-acquisition-target-150000778.html
IDGC Hires Executive Industries, a Division of Here To Serve Holding Corp. (OTC:HTSC) To Provide Corporate Marketing Services Including Investors Relations to IDGC
WHEATON, IL / ACCESSWIRE / June 30, 2021 / IDGlobal Corp. (OTC PINK:IDGC) is pleased to announce it has engaged Executive Industries, a division of Here to Serve Holding Corp, to provide corporate marketing services including investors relations.
The Company CFO, Sebastien C. DuFort stated "We are extremely excited about working with Executive Industries over the next year to assist us in building shareholder value."
ABOUT EXECUTIVE INDUSTRIES - (WWW.EXECINDUSTRIES.COM)
Executive Industries offers corporate advisory, consulting, and marketing services to both public and privately-owned companies. Executive Industries helps entities with corporate strategy, negotiation, corporate structure, marketing, and executive management decisions.
Executives empowering, solving, and anticipating problems before it impacts your business is a vital part of the Executive Industries business model. Executive Industries specializes in innovative solutions for every facet of your business. There is no such thing as a generic industry solution from Executive Industries. As your in-house executive advisors and consultants, we strategically develop our clients a personalized plan and organize and deliver executable solution management can understand. We do not waste our client's time by being redundant and we show management the highest respect for their time. Our communications with our clients are timely and unambiguous as Executive Industries puts our client's opinions, responsibility, and limited time before anything else. Executive Industries will always be ready to help your public company make the required strategical moves to save itself from a bad situation or analyze a great idea that could be a game-changer. Executive Industries is the ultimate team member that is always analyzing your business as if it is ours as well.
Whether you are looking for market awareness packages that are affordable and are highly effective or are looking for discount press release packages that are discounted for Executive Industries clientele only, the team at Executive Industries will assist you through the public company process. Executive Industries deals with some of the largest IR/PR companies in the industry and can save your public company thousands off, of these must-have services. We are experts at generating market interest and liquidity to help ensure your public company's success.
ABOUT NOVEDA
Noveda Technologies is an innovative leader in real-time, web-based energy and water monitoring. The company's patented software solutions help reduce energy and water usage, optimize renewable energy systems, and reduce the carbon footprint for customers across commercial, retail, government, education and utility sectors. Currently, headquartered in White Plains, New York, Noveda is focused as a pure play, Software as a Service, (SaaS) provider.
IDGC's Plan of Operations.
IDGC is an emerging growth company under the JOBS Act of 2012 and, as a diversified holding company, will focus on emerging and middle-market international investment opportunities through its subsidiaries. IDGlobal Corp. is an organization engaged in the business of fostering early-stage companies through the different developmental phases until the companies have sufficient financial, human, and physical resources to function on their own.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Please read the full disclaimer at www.idglobalcorp.io.
CONTACT:
Executive Industries
855-464-2535
(brian@privateequitymarkets.us)
SOURCE: ID Global Corporation
View source version on accesswire.com:
https://www.accesswire.com/653680/IDGC-Hires-Executive-Industries-a-Division-of-Here-To-Serve-Holding-Corp-OTCHTSC-To-Provide-Corporate-Marketing-Services-Including-Investors-Relations-to-IDGC
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process
Press Release | 06/30/2021
Jackson Center, Pennsylvania--(Newsfile Corp. - June 30, 2021) - Halberd Corporation (OTC Pink: HALB) announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies. This simplified method for the removal of disease-causing antigen(s) utilizes more conventional medical equipment found in hospitals and clinics and utilizes our patented extracorporeal treatment process. The method promises to simplify the commercial stocking and delivery of treatment materials and reduces costs associated with administration of treatments.
William A. Hartman, Halberd's Chairman, President & CEO, stated, "This simplified treatment process will be developed simultaneously with the radio frequency & laser emissive energy concepts. Halberd will initially target this process for application to the treatment of Alzheimer's Disease, which will involve three peptide/protein antigens - tau, phosphorylated tau, & beta amyloid - plus four inflammatory cytokines linked to the development and progression of Alzheimer's Disease. Details forthcoming as provisional patent applications are being prepared while development work continues. We are extremely excited about this concept since it reduces development time and cost while offering greater acceptability in the market and greater commercial opportunities for Halberd Corporation."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation
Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
https://www.otcmarkets.com/stock/HALB/news/Halberd-Corp-Discovers-a-Proprietary-Disease-Causing-Antigen-Removal-Process?id=309600
Better sooner than later. CUBV. :)
A massive end of the day for GGII. GLTA.
Penny talk is over. We are aiming much higher! $$$NSAV$$$
What a spirit! $$$NSAV$$$
TOTALLY AGREE!!! $$$NSAV$$$
GGII Green Globe - Hempacco to Be Featured in New Hemp and Cannabis Documentary Debuting at Sonoma Film Festival
Press Release | 06/25/2021
San Diego, California--(Newsfile Corp. - June 25, 2021) - Green Globe International Inc. - Hempacco (OTC Pink: GGII) ("GGII") the leading herb and hemp cigarette manufacturer, in their mission of Disrupting Tobaccoâ„¢, today announced that its Chairman and Chief Executive Officer, Sandro Piancone, will be featured in the debut of "Barely Legal," a documentary that provides a thought provoking look at cannabis' history of illegality, recent legislation to decriminalize hemp and cannabis and the confusion it has caused when it comes down to the specific laws governing this new industry. As one of the pioneers of the emerging hemp cigarette industry, Mr. Piancone was selected to present the industry's views on America's changing hemp and cannabis laws and its impact on the tobacco industry as well as the mainstream consumer.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7978/88664_0219c49d74ff8b4e_002full.jpg
RealStuffSmokables.com Hemp CBD Cigarettes
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7978/88664_0219c49d74ff8b4e_002full.jpg
Barely Legal, which stars Stephen Dorff and is directed by Emmy-winning director Casey Tebo, will debut at Sonoma International Film Festival's "Summerfest 2021", an event co-sponsored by Hempacco, on August 7, 2021, at Andrews Hall, located in Sonoma County, California.
Barely Legal was produced by Cross Creek Pictures, a premiere independent production company. Started by private business investors Timmy Thompson and Tyler Thompson in the fall of 2009, Cross Creek Pictures' films have grossed over $1.2 billion worldwide and have been nominated for 13 Academy Awards, 14 Golden Globes and 23 BAFTAs; including 3 Academy Award wins, 3 BAFTA wins, and 2 Golden Globes wins.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7978/88664_img1_550.jpg
CBD Cigarettes TheRealStuffSmokables.com Hemp Smokables
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7978/88664_img1.jpg
"It is an honor to have been selected by one of Hollywood's most influential production houses to represent the booming hemp cigarette industry in the highly-anticipated debut of Barely Legal," said Sandro Piancone, Chairman and CEO of Green Globe International, Inc. "Through this thought-provoking documentary, the director of Barely Legal has done a phenomenal job of explaining how recent reforms in the nation's hemp and cannabis laws have created over a million new jobs and helped a number of states from shutting down due to tax revenues of close to a billion dollars in some cases. And finally, the debut of Barely Legal is just the latest initiative that clearly presents the health benefits of hemp versus nicotine when discussing the dangers of the tobacco industry," concluded Mr. Piancone.
?"We are excited to work with Sandro and the experience of learning about The Real Stuff Hemp CBD Cigarettes," said Timmy Thompson, Chief Executive Officer of Cross Creek Pictures. "We are excited to be a participant in the Sonoma Film Festival this year and hope this documentary will shed some light on the history of the hemp and cannabis plant as well as the extraordinary benefits derived from it," concluded Mr. Thompson.
About Green Global International Inc. (GGII) - Hempacco, Co. Inc.:
Green Global International Inc. and its wholly owned subsidiary Hempacco Co., Inc. are Disrupting Tobacco'sâ„¢ nearly $1 Trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing consumer goods, including Herb Smokables, CBG, and CBD Hemp cigarettes. The Company owns and licenses intellectual property, has conducted extensive research and development, and is engaged in manufacturing and sales of smokable Hemp brands, including The Real Stuffâ„¢ Hemp Smokables. Hempacco Co., Inc.'s operating segments include joint-venture private label agreements and sales, Intellectual Property licensing, and the development and sales of inhouse brands using patented counter displays as well as six hundred Kiosk vending machines called HempBoxesâ„¢.
https://www.otcmarkets.com/stock/GGII/news/GGII-Green-Globe---Hempacco-to-Be-Featured-in-New-Hemp-and-Cannabis-Documentary-Debuting-at-Sonoma-Film-Festival?id=309007
Dear Bonous, ones again I would like to thank you VERY MUCH for posting all the tweets from NSAV in a very timely manner. I appreciate very much your effort in this regard. GLTY.
RushNet Inc. (OTCMKTS: RSHN) Target heliosDX Collaborates with Verb Technology To Use verbLIVEand verbTEAMS
https://topnewsguide.com/2021/06/23/rushnet-inc-otcmkts-rshn-target-heliosdx-collaborates-with-verb-technology-to-use-verbliveand-verbteams/
What they need is a big capital infusion and a rapid customers grow. $$$NSAV$$$
I expect PR next week. RSHN.
I expect PR next week. JMO. $$$NSAV$$$
I'm here, waiting for .25 C - $3. $$$NSAV$$$
It's time to move UP. $$$NSAV$$$.
"$RSHN You just never know!" The question is that good or bad?
What would be huge discount for you? For me it would have to @ 50%, it isn't going to happen.
Hey boiled bulba, hopefully we'll move this week. NSAV.
Hey boiled bulba, who cares for all of these, we need substance from NSAV.
Halberd Corporation's Proprietary Technology for Alzheimer's Disease Enters Stage 4 of 7 Stage Process
Press Release | 06/21/2021
Jackson Center, Pennsylvania--(Newsfile Corp. - June 21, 2021) - Halberd Corporation's (OTC Pink: HALB) proprietary technology enters stage 4 to address Alzheimer's Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means. Currently, there is no known effective treatment for Alzheimer's Disease which afflicts over 40 million people worldwide, equivalent to the combined population of the states of Florida and New York.
The seven (7) stages in Halberd's program are as follows:
Identifying target disease(s); (Done)
Creating patentable antibodies vs target disease(s); (Done)
Combining antibodies with metallic particles; (Done)
Eradicating the antibody-disease combination through radiofrequency waves, laser or other proprietary means; (In-process)
Conducting animal tests to establish the safety and efficacy; (Preliminary Planning)
Conducting human testing
Obtaining FDA Certification
Halberd has completed Steps 1-3. Step 4 is underway at Youngstown State University (YSU), under the direction of Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Sciences Department. Dr. Sturrus, stated, "The uniqueness of the methodology and approach has presented some equally unique problems. The team is working to overcome and resolve these challenges. We have had to invent measurement techniques; resolve power, frequency and time exposure issues; particle size optimization; etc. Some of these issues persist, but all of them are being addressed."
William A. Hartman, Halberd's Chairman, President & CEO, commented, "As a team, Halberd and its two state university partners along with GreenBioAZ remain 100% focused on developing an effective treatment for Alzheimer's Disease. Recently we announced the identification of three target antigens to eliminate by our process. After consulting with experts, we have broadened our list of target antigens to include a proprietary list of contributing inflammatory cytokines which increases our probability of success. All of the work Halberd has done to date has laid the foundation for our current program to treat Alzheimer's disease utilizing our patented and patent-pending technologies."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter: @HalberdC
About Halberd Corporation.
Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
https://www.otcmarkets.com/stock/HALB/news/Halberd-Corporations-Proprietary-Technology-for-Alzheimers-Disease-Enters-Stage-4-of-7-Stage-Process?id=308077
Hey, apparently it was BULBA news. LOL.
Is it supposed to be big news today?